Login to Your Account

Up To 19 Targets Involved

Galapagos Gets €17M Up Front From Janssen In RA Partnership

By Jennifer Boggs

Thursday, October 25, 2007

No Abstract


Staff Writer

Galapagos NV's drug discovery programs got a major shot in the arm with a multitarget, potential multimillion-dollar rheumatoid arthritis deal with Johnson & Johnson unit Janssen Pharmaceutica NV.

At its peak, the collaboration could bring Galapagos as much as €1 billion (US$1.43 billion) in up-front payments, license fees and milestones, and could involve as many as 15 to 19 targets.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription